Why the study?
Reliable scores to predict mortality following surgery for type A acute aortic dissection are lacking, prompting evaluation of the newly developed GERAADA score compared with EuroSCORE II.
Does the Clinical-GERAADA score improve prediction of 30-day mortality compared to EuroSCORE II in patients undergoing type A acute aortic dissection surgery?
Population
207 consecutive patients undergoing TAAAD repair at the Bristol Heart Institute
Comparison
Clinical-GERAADA score vs Radiological-GERAADA score vs EuroSCORE II
Design
Observational cohort study
Follow-up
30 days
Key result
The Clinical-GERAADA score demonstrated strong discriminative power for predicting 30-day mortality after TAAAD surgery (AUC 0.80; 95% CI 0.71-0.89), outperforming EuroSCORE II (AUC 0.77).
Authors
Loading...
Clinical-GERAADA may improve TAAAD operative risk prediction over EuroSCORE II; leaves open need for prospective validation before routine adoption.
Observational (n=207)
No
Does the Clinical-GERAADA score improve prediction of 30-day mortality compared to EuroSCORE II in patients undergoing type A acute aortic dissection surgery?
Effect estimate: AUC 0.80 (95% CI 0.71-0.89)
Absolute Event Rate: 0.8% vs 0.77%
The Clinical-GERAADA score, which incorporates both clinical and radiological evidence of malperfusion, provides strong discriminative power for predicting 30-day mortality after type A aortic dissection surgery, outperforming EuroSCORE II.
Gemelli et al. (2023) conducted an observational in Type A acute aortic dissection (TAAAD) (n=207). Clinical-GERAADA score vs. EuroSCORE II and Radiological-GERAADA score was evaluated on 30-day mortality prediction (AUC) (AUC 0.80, 95% CI 0.71-0.89). The Clinical-GERAADA score demonstrated strong discriminative power for predicting 30-day mortality after TAAAD surgery (AUC 0.80; 95% CI 0.71-0.89), outperforming EuroSCORE II (AUC 0.77).